messag tesaro report full-year financi see press releas
quarter sale parp inhibitor set ovarian recurr mainten
million million howev zejula sale came
consensu estim million vs guidanc million
full-year zejula sale came million provid list
key point fourth quarter call well post-cal comment manag
pt decreas lower revenu estim zejula
primari factor contribut somewhat mute declin preval
pool patient substanti preval pool exist time launch
larg diminish led excess demand tsro
manag believ two primari pool patient left penetr
incid recurr mainten patient incid treatment patient pool
incid recurr mainten patient roughli unit state revenu
contribut incid recurr mainten popul rapidli grow term
penetr current durat therapi month month
remain preval pool patient progress stop therapi
compli top key point quarter call post-cal
comment made manag
guidanc zejula revenu million approxim
revenu expect come demand germani given ou approv zejula
end manag expect penetr incid recurr
mainten popul longer durat therapi month month
sale current mainten label million expect
compil penetr incid recurr mainten
popul durat therapi month tsro intend introduc tablet
place pillscurr mg pills/capsul per day dosag strength
mg mg mg manag continu believ peak market opportun
ovarian cancer billion world-wide
radar analysi data indic predictor earli dose modif
mg characterist associ thrombocytopenia
includ bodi weight less lb baselin platelet tsro
describ predictor physician importantli see
new script mg dose approxim patient dose reduc
predictor thrombocytopenia aid physician appropri dose patient
minim hematolog toxic radar data present march
gynecolog oncolog confer
believ valu proposit tsro lie label expans zejula
upcom data compani immun oncolog program data zejula label
expans expect readout topacio data platinum-resist ovarian
cancer schedul present march gynecolog meet march
topacio patient trial evalu niraparib zejula plu keytruda anti-
antibodi triple-neg breast cancer tnbc ovarian cancer
data ovarian cancer cohort tnbc schedul present
american societi clinic oncolog meet june
prima studi first-lin ovarian cancer complet enrol studi
patient expect readout august quadra trial registr
trial patient ovarian cancer receiv three line therapi
data expect avail also present june
final combin trial platinum-sensit ovarian cancer bevacizumab
conclud accord manag data bravo trial
brca mutant breast cancer publish peer review journal
page analyst certif import disclosur
data topacio discuss fda advic futur trial trial
design file strategi
tsro registr trial known garnet
msi-high tumor much like merck keytruda data studi date
present american associ clinic research april
final readout expect accord clinic trial gov amber studi
combin antibodi antibodi data
societi immunotherapi confer novemb phase dose
antibodi also demonstr novemb
initi data jasper trial phase niraparib combin
inhibitor avail
tsro believ peak sale indic compani
seek billion million estim msi-h tumor
base anaphylaxi occur varubi iv tsro look out-licens
product continu market varubi oral tablet
compani expect year-end cash expect approxim million
zejula estim oc
bc oc bc
price target decreas
lower price target tesaro chang price target
reflect chang made model primarili driven decreas revenu estim
zejula beyond well discontinu compani varubi iv product
price target base dcf analysi use unchang
discount rate reflect risk adjust alreadi made futur cash unchang
base perform manag commentari call guidanc
made adjust model lower sale estim
niraparib zejula ovarian cancer base guidanc provid manag bring
fy estim also taken estim varubi iv
sale given compani discontinu sale product addit
increas oper expens reflect increas spend clinic develop
product launch also lower cog estim outer year reflect
lower cost good result tablet regimen expect implement
come year model profit net incom approxim
valuat risk
valuat price target base forward sum-of-the-part dcf
analysi includ risk-adjust revenu rolapit zejula rolapit oral
formul chemotherapy-induc vomit includ revenu though note
longer includ rolapit iv sale valuat due recent discontinu
product model profit tsro gener ep
valuat appli unchang discount rate reflect risk adjust alreadi
made futur cash flow unchang termin growth rate
risk risk rate price target includ limit tsro failur
gain regulatori approv rolapit inabl execut commerci
rolapit lower-than-expect /ex-u rolapit sale longer term key
risk includ unfavor clinical/regulatori outcom zejula ovarian cancer breast
page analyst certif import disclosur
thousand except per-shar figur
niraparib oc
niraparib bc
niraparib nsclc
io portfolio tnbc
develop licens agreement
grant contract
good
goods-intang amort
mileston payment mrk/opko
acquir in-process research develop
incom loss oper
compani report guggenheim secur llc
page analyst certif import disclosur
